Platinum-resistant Ovarian Cancer study: MEN2501
Official title A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
ClinicalTrials.gov ID: NCT07226427
What this study is testing
What is MEN2501?
MEN2501 is an investigational oral tablet being studied as a potential treatment for platinum-resistant ovarian cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find the safest and most effective dose of the new drug MEN2501. It also checks how the drug works in the body and whether it helps shrink tumors.
- Who it's for
- Adults who have ovarian cancer that has stopped responding to platinum-based chemotherapy.
- What's involved
- Participants will receive the new drug MEN2501 alone. They will undergo regular medical tests to monitor their health, blood levels of the drug, and how the cancer is responding.
- Time commitment
- The study involves ongoing visits for treatment and testing, but the specific total duration is not listed in the provided text.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube...
You likely can't join if
- Participants with primary platinum-refractory disease.
- Note: Other protocol-defined inclusion/exclusion criteria may apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Springdale, Arkansas, United States
- New Haven, Connecticut, United States
- Sarasota, Florida, United States
- Boston, Massachusetts, United States
- Detroit, Michigan, United States
- Rochester, Minnesota, United States
- Fairfax, Virginia, United States
- South Brisbane, Queensland, Australia
- Aberfoyle Park, Australia
- Barcelona, Spain
- Madrid, Spain
- Pamplona, Spain
- Pozuelo de Alarcón, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Springdale, Arkansas, United States; New Haven, Connecticut, United States; Sarasota, Florida, United States; Boston, Massachusetts, United States; Detroit, Michigan, United States; Rochester, Minnesota, United States and 7 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.